Web-Based Program Reduces Risk of Diabetes in Women
Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.
Oral Semaglutide Effective Regardless of Background T2D Therapy Use
An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.
Empagliflozin Decreases Risk of Heart Failure Hospitalization
The drug also reduced the risk of myocardial infarction and stroke.
Testosterone, Lifestyle Program Reduce Risk of Type 2 Diabetes in Men
Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.
State of Diabetes Care in 2020 with Robert Busch, MD
Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.
Todd Hobbs, MD: Positive Results of Once-Weekly Insulin Icodec Vs Glargine
Todd Hobbs, MD, breaks down research presented at ADA 2020.
Serge Jabbour, MD: Incidence and Impact of Herpes Zoster in T2DM Patients
Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.
Ertugliflozin Noninferior to Placebo for Cardiovascular Safety in VERTIS-CV
Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.
Long-Term Lifestyle Program, Metformin Both Reduce Risk of Type 2 Diabetes
The prevention of type 2 diabetes is possible and has important clinical benefits.
Youth, Young Adults Have Worse Glycemic Control Than in the Past
Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.
Metformin Use Associated with Decreased PTSD Symptoms in Diabetic Veterans
An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.
Itamar Raz, MD: Impact of Dapagliflozin on Rapid Decline of eGFR
An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.
Paolo Pozzilli, MD: Ladarixin, a CXCR1/2 inhibitor, in Type 1 Diabetes
Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.
Understanding Autoimmune Triggers Leading to Type 1 Diabetes in Children
An investigator provides an update on the TEDDY study.
Sirimon Reutrakul, MD: Using CPAP for Diabetes and Sleep Apnea
Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.
Bruce Bode, MD: Impact of COVID-19 on Diabetes Care and Endocrinology
A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.
FDA Approves FreeStyle Libre 2 Integrated Continuous Glucose Monitor
The monitor is approved for children and adults 4 years and older with diabetes.
Meg Jardine, MBBS, PhD: Mediators and Pathways of Canagliflozin's CV Benefit
Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.
Dapagliflozin Use Could Reduce Risk of Developing Type 2 Diabetes
A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.
Riccardo Perfetti, MD, PhD: AT-001 for Diabetic Complications
Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.
Medicaid Expansion Positive For Minorities With Diabetic Foot Ulcerations
Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.
Ildiko Lingvay, MD: Switching from Other GLP-1s to Once-Weekly Semaglutide
Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.
Christopher Sorli, MD: Basal Insulin and GLP-1 for Type 2 Diabetes
Christopher Sorli, MD, describes the results of a study showing the need for simultaneous therapy rather than sequential.
Hui Shao, MD, PhD: Life Expectancy of Patients with Type 2 Diabetes Mellitus
Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.
Marc Penn, MD: Hepatic Directed Vesicle Insulin for Hypoglycemic Control
Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.
Initial eGFR Decline with Empagliflozin Has No Impact on Reduction in CV Death
Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.
Preventing Hypoglycemia, Hyperglycemia with Insulin and Glucagon Coadministration
Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.
REDUCE-IT DIABETES Strengthens Icosapent Ethyl's Safety, Efficacy Profile
Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.
Dapagliflozin Effective Regardless of Background Diabetes Therapies
Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.
Sensor-Based Glucose Monitor Reduces Diabetic Ketoacidosis Hospitalizations
Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.
